3rd Quarter - Report

ALKERMES, INC. for ALKERMES, INC.

Firm
Client
Income
—
Expenses
$580,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Patient access and maintain six protected classes for depressions and schizophrenia under Medicare Part D; S. 2327 - Seniors Prescription Drug Relief Act; H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act; H.R. 19 - Lower Costs, More Cures Act; H.R.5260 - Reduced Costs and Continued Cures Act; Prescription Drug pricing legislation - Build Back Better Act - H.R. 5376 & Senate amendments Ensure patient access to behavioral health services and treatments through telehealth H.R. 5376 - Inflation Reduction Act of 2022

LobbyistCovered position, as disclosed
MEGAN JACKSON —
ZACHARY MICHAEL MARSHALL —
PETER NORMAN —

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 19 (117th), S. 2327 (117th), H.R. 5376 (117th), H.R. 5260 (117th), H.R. 3 (117th)

Health Issues HCR

Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; H.R. 7667 & S. 4348 - Prescription Drug User Fee Agreement reauthorization Awareness of need for transparency and patient access within the 340B program H.R. 6833 - Making continuing appropriations for fiscal year 2023, and for other purposes

LobbyistCovered position, as disclosed
WILLIAM PATRICK HIBBS —
MEGAN JACKSON —
ZACHARY MICHAEL MARSHALL —
PETER NORMAN —

Contacted: Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); Substance Abuse & Mental Health Services Administration (SAMHSA); SENATE; Office of Natl Drug Control Policy (NDCP); Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES

Bills named: H.R. 7667 (117th), H.R. 6833 (117th), S. 4348 (117th)

Alcohol and Drug Abuse ALC

Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings; H.R.955 - Medicaid Reentry Act of 2021; Expand funding and flexibility to address all substance use disorders;

LobbyistCovered position, as disclosed
WILLIAM PATRICK HIBBS —
MEGAN JACKSON —
ZACHARY MICHAEL MARSHALL —
PETER NORMAN —

Contacted: Veterans Affairs, Dept of (VA); Justice, Dept of (DOJ); HOUSE OF REPRESENTATIVES; SENATE; Substance Abuse & Mental Health Services Administration (SAMHSA); Health & Human Services, Dept of (HHS); Executive Office of the President (EOP)

Bills named: H.R. 955 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.